Webinar features glycoselect

New webinar on glycoanalytics features GlycoSeLect

Last month, BioPharm International hosted a webinar on Novel High-Throughput Glycoanalytics for Biopharmaceuticals, sponsored by Sartorius, and aimed at those interested in learning more about the detection of glycans in biopharmaceutical samples.

During the presentation, Victoria Smith and Lewis Wharram from the Center for Processes and Innovation (CPI), Darlington, UK, reviewed the high-throughput method for glycan analysis that uses the Octet technology in combination with GlycoSeLect’s Recombinant Prokaryotic Lectins (RPLs). The platform was developed in collaboration between CPI, GlycoSeLect Ltd, Allergan and ForteBio, and funded by Innovate UK.

Our project partners at CPI explained how our RPLs were integrated into ForteBio’s biosensor platform and analysed the robustness of the quantitation assay for two biotherapeutics provided by Allergan Biologics: FSH (follicle-stimulating hormone) and Eylea (Fc fusion protein). The samples were tested for terminal β1-4 galactose and sialic acid structures using RPL-Gal1 and RPL-Sia1, respectively.

The speakers concluded that:

  • This technology is a successful method for the quantification of glycosylated proteins.
  • The platform yielded good results, even simulating in-process conditions.
  • It provides a rapid and high-throughput technique for the analysis of glycans during the development and manufacturing of biopharmaceuticals.

“We are delighted to see that our RPL products contributed greatly to a high throughput glycoanalysis platform for intact glycoproteins in the biopharmaceutical industry. Thanks to BioPharm International for hosting and Sartorius for sponsoring the webinar,” expressed GlycoSeLect’s CEO, Robert Dunne.

The webcast is available to watch on-demand for those who register through this link.

About GlycoSelect Ltd

GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.

More Stories